CN113047039A - Air filter material and preparation method thereof - Google Patents
Air filter material and preparation method thereof Download PDFInfo
- Publication number
- CN113047039A CN113047039A CN202110307796.5A CN202110307796A CN113047039A CN 113047039 A CN113047039 A CN 113047039A CN 202110307796 A CN202110307796 A CN 202110307796A CN 113047039 A CN113047039 A CN 113047039A
- Authority
- CN
- China
- Prior art keywords
- weight
- extract
- air filtration
- air
- filtration material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title claims abstract description 90
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 229940094952 green tea extract Drugs 0.000 claims abstract description 31
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 31
- 239000008367 deionised water Substances 0.000 claims abstract description 15
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 22
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 20
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 241001092070 Eriobotrya Species 0.000 claims description 17
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims description 17
- 241000205585 Aquilegia canadensis Species 0.000 claims description 15
- 241000533293 Sesbania emerus Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 229940069765 bean extract Drugs 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 9
- 238000007598 dipping method Methods 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 6
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 6
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000004750 melt-blown nonwoven Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 32
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 31
- 241000700605 Viruses Species 0.000 abstract description 5
- 241000712461 unidentified influenza virus Species 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 241000008921 Avian coronavirus Species 0.000 abstract description 2
- 241001529459 Enterovirus A71 Species 0.000 abstract description 2
- 241000991587 Enterovirus C Species 0.000 abstract description 2
- 241000588724 Escherichia coli Species 0.000 abstract description 2
- 206010069767 H1N1 influenza Diseases 0.000 abstract description 2
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 201000010740 swine influenza Diseases 0.000 abstract description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 19
- 241000196324 Embryophyta Species 0.000 description 9
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 5
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 5
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 5
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 5
- 235000001368 chlorogenic acid Nutrition 0.000 description 5
- 229940074393 chlorogenic acid Drugs 0.000 description 5
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 5
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 5
- 238000005470 impregnation Methods 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- -1 silver ions Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940096998 ursolic acid Drugs 0.000 description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 3
- 241000218628 Ginkgo Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 238000004887 air purification Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/10—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing oxygen
- D06M13/224—Esters of carboxylic acids; Esters of carbonic acid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/10—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing oxygen
- D06M13/184—Carboxylic acids; Anhydrides, halides or salts thereof
- D06M13/188—Monocarboxylic acids; Anhydrides, halides or salts thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/10—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing oxygen
- D06M13/184—Carboxylic acids; Anhydrides, halides or salts thereof
- D06M13/203—Unsaturated carboxylic acids; Anhydrides, halides or salts thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/04—Additives and treatments of the filtering material
- B01D2239/0442—Antimicrobial, antibacterial, antifungal additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/10—Filtering material manufacturing
Landscapes
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of air filtration, in particular to an air filtration material and a preparation method thereof, and especially relates to an antibacterial and antiviral air filtration material and a preparation method thereof. In the present invention the air filtration material is treated in a pharmaceutical composition comprising: 0.1-2 parts by weight of green tea extract; and the balance of deionized water. The air filter material with the antibacterial and antiviral functions can directly contact with the skin, is safe and reliable, and has no stimulation to the skin; and can effectively kill bacteria and viruses in the air, such as staphylococcus aureus, escherichia coli, H1N1 influenza virus, H3N2 influenza virus, enterovirus 71, poliovirus, avian coronavirus and the like, so as to prevent the spread of diseases.
Description
Technical Field
The invention relates to the field of air filtration, in particular to an air filtration material and a preparation method thereof, and especially relates to an antibacterial and antiviral air filtration material and a preparation method thereof.
Background
Nowadays, with the continuous improvement of living standard of people, the requirement on environment is also correspondingly improved. Air filters, purifiers, fresh air blowers and the like are continuously available in the market. Meanwhile, matched functional (such as antibacterial, antiviral, antiallergic and the like) materials are gradually shown, especially in 2020, the appearance of COVID-19 virus, and antibacterial and antiviral products are urgent needs of people. Currently, the most commonly used antibacterial and antiviral functional materials are inorganic materials and organic materials. The inorganic substances include silver, copper, zinc, titanium, etc., and among them, silver ions are most widely used. The organic compounds include halides, organotin, isothiazole, pyridine metal compounds, imidazolone, aldehyde compounds, quaternary ammonium salts, and the like. Both types of applications have certain limitations. For example, silver ions have the common disadvantage of ionic oxidation and the danger of cytotoxicity makes them useless in many skin-contacting materials. However, the safety of organic materials is yet to be studied, and the organic materials have the disadvantages of poor heat resistance, short effective period and the like.
Thus, there is a need for a safe, reliable, skin-contactable, antimicrobial and antiviral material that can be incorporated into air filtration materials.
Disclosure of Invention
An object of exemplary embodiments of the present invention is to solve the above and other disadvantages of the prior art and to provide an air filter material having antibacterial and antiviral functions to remove bacteria and/or viruses from the environment. In the present invention, the air filter material is provided by adding an antibacterial and antiviral agent thereto. The antibacterial and antiviral agent is derived from a plant source, for example, extracted from a plant (e.g., medicinal material), and the agent can be directly introduced into a human body. Therefore, the air filter material with the antibacterial and antiviral functions can directly contact the skin, is safe and reliable, and has no stimulation to the skin; and can effectively kill bacteria and viruses in the air, such as staphylococcus aureus, escherichia coli, H1N1 influenza virus, H3N2 influenza virus, enterovirus 71, poliovirus, avian coronavirus and the like, so as to prevent the spread of diseases. .
In one aspect, the present invention provides an air filtration material, wherein the air filtration material is treated in a pharmaceutical composition comprising:
0.1-2 parts by weight of green tea extract; and
the balance of deionized water;
wherein the green tea extract is EGCG.
In some embodiments, the pharmaceutical composition further comprises:
0.1-1 weight parts of ginkgo biloba extract;
0.1-1 weight parts of honeysuckle extract;
0.1-1 parts by weight of loquat leaf extract;
0.1-1 parts by weight of green coffee bean extract; or
One or more of them in combination.
In some embodiments, the green tea extract, the ginkgo biloba extract, the honeysuckle extract, the loquat leaf extract, and the green coffee bean extract are in a powder form or a granular form, and have an average particle size of 80 to 100 mesh.
In some embodiments, the air filtration material comprises a nonwoven material.
In some embodiments, the nonwoven material comprises a wet laid nonwoven material, a dry laid nonwoven material, a meltblown nonwoven material, a needle punched nonwoven material, or a combination of one or more thereof. (ii) a
In some embodiments, the air filtration material further comprises a filter screen woven by warp and weft.
In another aspect, the present invention provides a method of manufacturing the air filter material, the method comprising:
(i) dissolving green tea extract in deionized water at 40-80 deg.C to provide a solution containing green tea extract;
(ii) optionally, dissolving ginkgo biloba leaf extract, honeysuckle flower extract, loquat leaf extract, green coffee bean extract in a solution comprising green tea extract at 40-80 ℃ to provide the pharmaceutical composition; and
(iii) applying the medicament composition to an air filtration material to provide a treated air filtration material.
In some embodiments, in step (iii), the medicament composition is applied to the air filtration material by dipping, spraying, coating; and/or
The treated air filtering material is dried by adopting a heating drying tunnel.
In a further aspect, the invention provides the use of the air filter material in filters, air conditioners and air cleaning devices.
In the invention, the antibacterial and antiviral medicament composition is of plant source, and is safe and reliable. In the pharmaceutical composition, the green tea extract EGCG is taken as the main component, other plant extracts (such as optional ginkgo leaf extract, honeysuckle extract, loquat leaf extract and/or green coffee bean extract) are taken as the auxiliary components, and the antibacterial and antitoxic effects of the pharmaceutical composition can be obviously improved by utilizing the synergistic effect of the main-auxiliary extracts. Moreover, the air filter material treated by the medicament composition can provide better antibacterial and antiviral effects, and is higher in safety and more environment-friendly. The antibacterial and antiviral medicament composition of the invention has no influence on the original functions of the filter, such as filtration efficiency, resistance, and the original functions of the filter, such as formaldehyde removal, negative ion removal and the like.
Drawings
The invention may be better understood by describing exemplary embodiments thereof in conjunction with the following drawings, in which:
FIG. 1 is a post-treatment finishing line for preparing an air filtration material in an embodiment of the present invention. Wherein, the mark 1 represents unreeling; reference numeral 2 denotes an immersion tank; reference numeral 3 denotes a drying tunnel; and 4, a winding.
Detailed Description
The present invention will be described more fully hereinafter with reference to exemplary embodiments thereof. These exemplary embodiments are described so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Indeed, this invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements.
Term(s) for
Unless otherwise defined, technical or scientific terms used in the claims and the specification should have the ordinary meaning as understood by those of ordinary skill in the art to which the invention belongs.
The green tea extract is epigallocatechin gallate (EGCG) with molecular formula of C22H18O11The structural formula is as follows:
loquat leaf extract: the main components comprise oleanolic acid, ursolic acid, triterpenic acids, sesquiterpenes, flavonoids, polyphenols, organic acids, etc. Wherein, the structural formulas of oleanolic acid and ursolic acid are as follows:
ginkgo leaf extract: the main components include flavonoids, terpenoids, lactones, phenolic acids, alkaloids, polyisoprene, etc. Wherein the phenolic acid has the following structural formula:
and (3) honeysuckle extract: the main component comprises chlorogenic acid. Wherein the chlorogenic acid has the following structural formula
Green coffee bean extract: the main components comprise chlorogenic acid and isomers thereof.
The term "applying" includes, but is not limited to, adding, dipping, spraying, coating (e.g., spraying), covering, and the like, is not limited to direct contact or indirect contact (e.g., the medicament package is attached to an air filter web), nor is it limited to partial or complete application.
Extract of plant
In the invention, the extract is of plant origin, and the plant includes tea leaves, loquat leaves, ginkgo leaves, honeysuckle, green coffee beans and other plants. In the present invention, the extract may be provided in the form of a solution or a solid. When provided in solution, the parts by weight of the extract are on a dry weight basis. For example, when the pharmaceutical composition comprises 0.1 to 2 parts by weight of the green tea extract, the 0.1 to 2 parts by weight means that the dry weight of the green tea extract accounts for 0.1 to 2 parts by weight after the solvent is removed.
In the present invention, the various extracts may be obtained in a commercially available manner, and preferably, the purity of the extract is 95%, 98% or more.
The green tea extract, the ginkgo leaf extract, the honeysuckle extract, the loquat leaf extract and the green coffee bean extract according to the present invention may be each in the form of powder or granules, and have an average particle size of 80 to 100 mesh, 80 to 95 mesh, 80 to 90 mesh, 80 to 85 mesh, 85 to 100 mesh, 85 to 95 mesh, 85 to 90 mesh, 90 to 100 mesh, 90 to 95 mesh or 95 to 100 mesh, for convenience of transportation, use and processing.
In the preparation of the pharmaceutical composition, the powdered or granular extracts may be first each dissolved in deionized water and the resulting solutions combined. The step-by-step mixing mode of the invention can better dissolve EGCG and other plant extracts in the green tea extract.
Pharmaceutical composition
In the present invention, the antibacterial and antiviral pharmaceutical composition contains green tea extract as a main ingredient. The pharmaceutical composition comprises 0.1-2 parts by weight, 0.1-1.5 parts by weight, 0.1-1.0 parts by weight, 0.1-0.5 parts by weight, 0.5-2 parts by weight, 0.5-1.5 parts by weight, 0.5-1.0 parts by weight, 1.0-2 parts by weight, 1.0-1.5 parts by weight, 1.5-2 parts by weight of green tea extract.
In one embodiment of the invention, the green tea extract is EGCG.
In the invention, the EGCG has good antibacterial and antiviral properties. But limited by its molecular structural characteristics, EGCG is poorly lipophilic and thus affects its ability to bind to viral proteins. In order to improve the binding capacity of EGCG and viruses, the inventor unexpectedly finds that by introducing some acidic substances (for example, plant-derived acids) into the pharmaceutical composition, the binding capacity of EGCG and viral proteins can be greatly enhanced to play a synergistic effect with EGCG, thereby improving the antiviral effect of the pharmaceutical composition and the air filtering material. In addition, the introduced plant source acid has the antibacterial and antiviral effects, and the replication process of the virus can be interrupted more effectively. Therefore, in some embodiments of the present invention, the antibacterial and antiviral pharmaceutical composition further comprises an extract of ginkgo biloba leaves, an extract of honeysuckle flowers, an extract of loquat leaves, an extract of green coffee beans, or a combination of one or more thereof, having an acidic substance therein.
In some embodiments, the antibacterial and antiviral pharmaceutical composition of the present invention further comprises 0.1 to 1 part by weight, 0.1 to 0.8 part by weight, 0.1 to 0.5 part by weight, 0.1 to 0.3 part by weight, 0.3 to 1 part by weight, 0.3 to 0.8 part by weight, 0.3 to 0.5 part by weight, 0.5 to 1 part by weight, 0.5 to 0.8 part by weight, 0.8 to 1 part by weight of the ginkgo biloba extract. In a specific embodiment, the antibacterial and antiviral pharmaceutical composition of the present invention further comprises 0.1 to 1 part by weight, 0.1 to 0.8 part by weight, 0.1 to 0.5 part by weight, 0.1 to 0.3 part by weight, 0.3 to 1 part by weight, 0.3 to 0.8 part by weight, 0.3 to 0.5 part by weight, 0.5 to 1 part by weight, 0.5 to 0.8 part by weight, and 0.8 to 1 part by weight of phenolic acid.
In some embodiments, the antibacterial and antiviral pharmaceutical composition of the present invention further comprises 0.1 to 1 part by weight, 0.1 to 0.8 part by weight, 0.1 to 0.5 part by weight, 0.1 to 0.3 part by weight, 0.3 to 1 part by weight, 0.3 to 0.8 part by weight, 0.3 to 0.5 part by weight, 0.5 to 1 part by weight, 0.5 to 0.8 part by weight, 0.8 to 1 part by weight of the honeysuckle extract. In a specific embodiment, the antibacterial and antiviral pharmaceutical composition of the present invention further comprises 0.1 to 1 part by weight, 0.1 to 0.8 part by weight, 0.1 to 0.5 part by weight, 0.1 to 0.3 part by weight, 0.3 to 1 part by weight, 0.3 to 0.8 part by weight, 0.3 to 0.5 part by weight, 0.5 to 1 part by weight, 0.5 to 0.8 part by weight, 0.8 to 1 part by weight of chlorogenic acid.
In some embodiments, the antibacterial and antiviral pharmaceutical composition of the present invention further comprises 0.1 to 1 part by weight, 0.1 to 0.8 part by weight, 0.1 to 0.5 part by weight, 0.1 to 0.3 part by weight, 0.3 to 1 part by weight, 0.3 to 0.8 part by weight, 0.3 to 0.5 part by weight, 0.5 to 1 part by weight, 0.5 to 0.8 part by weight, 0.8 to 1 part by weight of the extract of loquat leaves. In a specific embodiment, the antibacterial and antiviral pharmaceutical composition of the present invention further comprises oleanolic acid and/or ursolic acid in an amount of 0.1-1 part by weight, 0.1-0.8 part by weight, 0.1-0.5 part by weight, 0.1-0.3 part by weight, 0.3-1 part by weight, 0.3-0.8 part by weight, 0.3-0.5 part by weight, 0.5-1 part by weight, 0.5-0.8 part by weight, 0.8-1 part by weight.
In some embodiments, the antibacterial and antiviral pharmaceutical composition of the present invention further comprises 0.1 to 1 part by weight, 0.1 to 0.8 part by weight, 0.1 to 0.5 part by weight, 0.1 to 0.3 part by weight, 0.3 to 1 part by weight, 0.3 to 0.8 part by weight, 0.3 to 0.5 part by weight, 0.5 to 1 part by weight, 0.5 to 0.8 part by weight, 0.8 to 1 part by weight of green coffee bean extract. In a specific embodiment, the antibacterial and antiviral pharmaceutical composition of the present invention further comprises 0.1 to 1 part by weight, 0.1 to 0.8 part by weight, 0.1 to 0.5 part by weight, 0.1 to 0.3 part by weight, 0.3 to 1 part by weight, 0.3 to 0.8 part by weight, 0.3 to 0.5 part by weight, 0.5 to 1 part by weight, 0.5 to 0.8 part by weight, 0.8 to 1 part by weight of chlorogenic acid and isomers thereof.
Air filtering material
In the present invention, the air filter is not particularly limited as long as the pharmaceutical composition of the present invention can be applied to the air filter. In some embodiments, the air filtration material may be a nonwoven material, including but not limited to: a wet laid nonwoven, a dry laid nonwoven, a melt blown nonwoven, a needle punched nonwoven, or a combination of one or more thereof.
In a preferred embodiment, the air filter material further comprises a filter screen woven by warp and weft. In some embodiments, the air filtration screen comprises: one or more of a folded filter screen, a plane filter screen, filter paper, filter cloth and non-woven filter cloth.
Application of pharmaceutical compositions to air filtration materials
In a specific embodiment, the method of manufacturing the air filter material first comprises: dissolving green tea extract, folium Ginkgo extract, flos Lonicerae extract, folium Eriobotryae extract, and green coffee bean extract in deionized water at 40-80 deg.C, 40-70 deg.C, 40-60 deg.C, 40-50 deg.C, 50-80 deg.C, 50-70 deg.C, 50-60 deg.C, 60-80 deg.C, 60-70 deg.C or 70-80 deg.C respectively to provide a solution containing each extract. In some embodiments, the pharmaceutical composition is provided by first dissolving green tea extract at a temperature of 40-80 ℃, 40-70 ℃, 40-60 ℃, 40-50 ℃, 50-80 ℃, 50-70 ℃, 50-60 ℃, 60-80 ℃, 60-70 ℃ or 70-80 ℃, and then optionally dissolving ginkgo biloba extract, honeysuckle extract, loquat leaf extract, green coffee bean extract in a solution comprising green tea extract at a temperature of 40-80 ℃, 40-70 ℃, 40-60 ℃, 40-50 ℃, 50-80 ℃, 50-70 ℃, 50-60 ℃, 60-80 ℃, 60-70 ℃ or 70-80 ℃.
After obtaining the desired medicament composition, the medicament composition is applied to the air filtration material to provide a treated air filtration material. In the present invention, the pharmaceutical composition may be applied to the air filtration material by various means. As noted above, "applying" includes, but is not limited to, adding, dipping, spraying, coating (e.g., spraying), covering, and the like. Also, the medicament composition is not limited to a direct contact air filter material, but may include an indirect contact air filter material. For example, attached to an air filter screen by medicament packs. The attachment mode comprises that the filter screen is directly inserted into a folding mountain between folds of the filter screen or attached by glue, binding wires and the like. In addition, the medicament composition is not limited to being applied to the entire air filtration material, but also includes applying the medicament composition to a portion of the air filtration material.
In a specific embodiment, the method of manufacturing the air filter material includes: (i) dissolving green tea extract in deionized water at 40-80 deg.C to provide a solution containing green tea extract; (ii) optionally, dissolving ginkgo biloba leaf extract, honeysuckle flower extract, loquat leaf extract, green coffee bean extract in a solution comprising green tea extract at 40-80 ℃ to provide the pharmaceutical composition; and (iii) applying the medicament composition to an air filtration material to provide a treated air filtration material.
In step (iii), the medicament composition may be applied to the air filtration material by dipping, spraying, coating. In step (iii), the medicament composition may be applied to the adsorbent material by dipping, spraying, coating, and then attaching the adsorbent material to the air filtration material.
In a specific embodiment, the method for preparing the air filter material comprises the following steps:
(i) weighing a certain amount of green tea extract, dispersing in deionized water, dissolving at 40-80 deg.C, and stirring until the green tea extract is completely dissolved;
(ii) adding other plant extracts, dissolving at 40-80 deg.C, stirring for dissolving, standing, and making into antibacterial and antiviral medicinal composition;
(iii) (iii) placing the formulated pharmaceutical composition of step (ii) in an impregnation tank; and
(iv) unreeling the air filtering material, passing through a dipping tank, rolling, drying again, and then rolling for later use.
In the re-drying process, the drying can be carried out by adopting a heating drying tunnel under the following process parameters:
the heating drying tunnel is 3-15 meters long,
the heating area I is 60-170 ℃,
the heating area II is 60-170 ℃,
the heating area III is heated to 80-170 ℃,
the heating area IV is 80-170 ℃,
the temperature of the heating area V is 80-170 ℃,
a heating region VI 100-
Vehicle speed: 2-50 m/min.
Applications of
The air filter material of the present invention can be applied to filters, air conditioners and air purification devices. Specifically, the air filter material of the present invention can be used in air purifiers, household air conditioners, central air conditioners, fresh air blowers, etc., and air conditioning or purification systems of transportation vehicles.
Example 1:
the mixture of EGCG and loquat leaf extract is used to prepare the antibacterial and antiviral medicine composition. Based on the total weight of the pharmaceutical composition, the dry weight of EGCG is 0.4 parts by weight, the dry weight of the loquat leaf extract is 0.2 parts by weight, and the balance is deionized water.
The air filter material adopts dry-method non-woven fabrics, the thickness is 0.5mm, and the gram weight is 70 g/square meter.
The method comprises the following steps:
(i) dissolving EGCG in deionized water at 40-80 deg.C, and stirring to obtain solution containing green tea extract;
(ii) dissolving the extract of loquat leaves in a solution containing EGCG at 40-80 deg.C, stirring to dissolve, and standing to provide the pharmaceutical composition;
(iii) placing the medicament composition into an impregnation tank, and performing impregnation treatment on the air filter material in the impregnation tank; and
(iv) drying the air filtering material subjected to the dipping treatment, wherein the drying process parameters are as follows:
example 2:
an air filter material was prepared using the same procedure as in example 1, except that the following were specifically noted:
based on the total weight of the pharmaceutical composition, the dry weight of the EGCG is 0.4 weight part, the dry weight of the honeysuckle extract is 0.2 weight part, and the balance is deionized water.
The air filter material adopts wet-process non-woven fabrics, the thickness is 0.5mm, and the gram weight is 60 grams per square meter.
The drying process parameters are as follows:
example 3:
an air filter material was prepared using the same procedure as in example 1, except that the following were specifically noted:
based on the total weight of the pharmaceutical composition, the dry weight of the EGCG is 0.4 weight part, the dry weight of the ginkgo biloba extract is 0.2 weight part, and the balance is deionized water.
The air filter material adopts spun-bonded non-woven fabrics, the thickness is 0.3mm, and the gram weight is 40 g/square meter.
The drying process parameters are as follows:
example 4
An air filter material was prepared using the same procedure as in example 1, except that the following were specifically noted:
the dry weight of EGCG is 0.6 parts by weight, the balance being deionized water, based on the total weight of the pharmaceutical composition.
The air filter material adopts spun-bonded non-woven fabrics, the thickness is 0.3mm, and the gram weight is 40 g/square meter.
The drying process parameters are as follows:
example 5
The same procedure as in example 4 was used to prepare an air filter material, except that the following was specifically noted:
the dry weight of EGCG was 2 parts by weight, the balance being deionized water, based on the total weight of the pharmaceutical composition.
Examples 6 to 10
An air filter material was prepared by following the formulations of examples 6 to 10 shown in Table 1, using the same procedure as in example 1.
Table 1: formulation of pharmaceutical composition
Table 2: antibacterial and antiviral effects
The antibacterial rate is as follows: detection is carried out according to GB/T20944.3-2008 (oscillation method).
And (3) antivirus: the test was carried out according to ISO: 18184.
As shown in Table 2, examples 1 to 10 of the present invention are highly effective in antibacterial and antiviral properties. Also, example 1 had a better antiviral effect than example 4. In example 1, the 2-hour antiviral activity value and the 2-hour antiviral activity rate were 2.06 and 99.13%, respectively, which were higher than 1.86 and 98.62% in example 4.
Claims (9)
1. An air filtration material, wherein the air filtration material is treated in a pharmaceutical composition comprising:
0.1-2 parts by weight of green tea extract; and
the balance of deionized water;
wherein the green tea extract is EGCG.
2. The air filtration material of claim 1, wherein the medicament composition further comprises:
0.1-1 weight parts of ginkgo biloba extract;
0.1-1 weight parts of honeysuckle extract;
0.1-1 parts by weight of loquat leaf extract;
0.1-1 parts by weight of green coffee bean extract; or
One or more of them in combination.
3. The air filtration material according to claim 1, wherein the green tea extract, the ginkgo biloba leaf extract, the honeysuckle flower extract, the loquat leaf extract, and the green coffee bean extract are in a powder form or a granular form, and have an average particle diameter of 80 to 100 mesh.
4. The air filtration material of claim 1, wherein the air filtration material comprises a nonwoven material.
5. The air filtration material of claim 1, wherein the nonwoven material comprises a wet laid nonwoven material, a dry laid nonwoven material, a melt blown nonwoven material, a needle punched nonwoven material, or a combination of one or more thereof.
6. The air filtration material of claim 1, further comprising a filter screen woven by warp and weft.
7. A method of manufacturing an air filter material as claimed in any one of claims 1 to 6, said method comprising:
(i) dissolving green tea extract in deionized water at 40-80 deg.C to provide a solution containing green tea extract;
(ii) optionally, dissolving ginkgo biloba leaf extract, honeysuckle flower extract, loquat leaf extract, green coffee bean extract in a solution comprising green tea extract at 40-80 ℃ to provide the pharmaceutical composition; and
(iii) applying the medicament composition to an air filtration material to provide a treated air filtration material.
8. The method of claim 7, wherein in step (iii), the medicament composition is applied into the air filtration material by dipping, spraying, coating; and/or
The treated air filtering material is dried by adopting a heating drying tunnel.
9. Use of an air filter material according to any one of claims 1 to 6 in filters, air conditioners and air cleaning devices.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110307796.5A CN113047039A (en) | 2021-03-23 | 2021-03-23 | Air filter material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110307796.5A CN113047039A (en) | 2021-03-23 | 2021-03-23 | Air filter material and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113047039A true CN113047039A (en) | 2021-06-29 |
Family
ID=76514394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110307796.5A Pending CN113047039A (en) | 2021-03-23 | 2021-03-23 | Air filter material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113047039A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462996A (en) * | 2010-11-08 | 2012-05-23 | 佛山市顺德区阿波罗环保器材有限公司 | Manufacturing method of antibacterial and antiviral filter |
| CN110172823A (en) * | 2019-06-27 | 2019-08-27 | 四川大学 | A kind of preparation method of formaldehydeless water-fastness flame-retardant textile |
-
2021
- 2021-03-23 CN CN202110307796.5A patent/CN113047039A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462996A (en) * | 2010-11-08 | 2012-05-23 | 佛山市顺德区阿波罗环保器材有限公司 | Manufacturing method of antibacterial and antiviral filter |
| CN110172823A (en) * | 2019-06-27 | 2019-08-27 | 四川大学 | A kind of preparation method of formaldehydeless water-fastness flame-retardant textile |
Non-Patent Citations (2)
| Title |
|---|
| 刘亚华: "《侗族药物彩色图谱》", 31 August 2017, 贵州科技出版社 * |
| 陈锁: "天然植物提取物整理涤纶织物抗菌消臭性能研究", 《印染助剂》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103691314B (en) | A kind of deodorizing composition and application thereof | |
| CN101775745B (en) | Melt-down non-woven material, preparation method and product | |
| DE19618913A1 (en) | Gargle cup, antiviral mask, antiviral filter, fungicidal, antibacterial and antiviral filter, air purifier and air purifier humidifier | |
| CN101642582A (en) | Material with multi-functional long-acting slow-release effective components | |
| CN106637498A (en) | A kind of preparation method and application of self-aromatic natural antibacterial and deodorant fiber | |
| CN102733184A (en) | Finishing technology for aromatic anti-bacteria cotton textile | |
| CN105709262A (en) | Silver-loaded antibacterial dressing and preparation method thereof | |
| CN109825889B (en) | Regenerated cellulose fiber with cooling and bacteriostatic functions and preparation method thereof | |
| CN101716362B (en) | Bactericidal disinfectant material containing chlorine dioxide, and application thereof | |
| CN101732745A (en) | Nano medicine antibacterial and antiviral finishing agent as well as preparation method and finishing method thereof | |
| CN110106579A (en) | A kind of anti-bacterial fibre and preparation method thereof containing MOF | |
| CN106435824A (en) | A self-fragrant natural antibacterial and deodorant fiber | |
| CN106110856A (en) | A kind of except formaldehyde purifying agent | |
| US6156817A (en) | Functional form and process for the production of the same | |
| CN108560149A (en) | A kind of processing technology of high-performance antibiosis polypropylene spunbond non-woven fabrics | |
| CN108208040A (en) | A kind of plant air disinfectant and preparation method thereof | |
| CN104430554A (en) | Antimicrobial composition comprising ginseng extract and green tea extract, antimicrobial filter and method for manufacturing the same | |
| CN103583591A (en) | Repellent liquid | |
| CN113047039A (en) | Air filter material and preparation method thereof | |
| JPH10315A (en) | Antifungal antibacterial antiviral filter | |
| CN109395142A (en) | A kind of moisture absorption vapor-permeable type bacteriostatic wound dressing | |
| JP2002001024A (en) | Antibacterial filter and method for producing the same | |
| CN103815587B (en) | A kind ofly harmful fine particulates is effectively stoped in air to suck and mouth mask with bacteriostasis and preparation method thereof | |
| JP4035270B2 (en) | Functional molded product and method for producing the same | |
| CN108904380B (en) | Wet tissue with antibacterial function and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210629 |
|
| RJ01 | Rejection of invention patent application after publication |